Tuesday April 22, 2014 12:00 -3:00 pm
SC3: Epigenetic Assays and High-Throughput Screening*
Abdellah Allali-Hassani, Ph.D., Team Leader, Enzymatic Assays, Structural Genomics Consortium, University of Toronto
Karen Maegley, Ph.D., Associate Research Fellow, Integrative Biology and Biochemistry, Oncology, Pfizer, Inc.
Daniel K. Treiber, Ph.D., Senior Director, Research & Development, KINOMEscan Division, DiscoveRx Corporation
Topics to be Discussed:
- Overview of current screening strategies for hits
- Development of biochemical/biophysical assays
- Development of phenotypic/cell-based assays
- Application to Histone Methyltransferases, Demethylases & BET bromodomain
Dr. Abdellah Allali-Hassani is a Senior Researcher/Team Leader at the Structural Genomics Consortium working with the Molecular Biophysics group at SGC Toronto since 2005. Dr. Allali-Hassani played a central role in setting-up the SGC screening platform. His effort culminated in the development of robust assays of many therapeutically important targets. His current focus is on the screening of novel epigenetic targets coming either from in-house biology studies or in the framework of collaborations with Academia or big Pharma. He is a coauthor of more than 40 scientific publications.
Dr. Karen Maegley has two decades of experience in biochemical and enzymatic characterization of potential drug targets. As an Associate Research Fellow at Pfizer, Karen directs the epigenetics biochemistry lab within the Oncology Research Unit. The focus of the epigenetics biochemistry lab is to obtain a deep understanding of potential drug targets through biochemical and enzymatic characterization and through collaboration with structural biology and biophysics groups. The lab is also responsible for assay development in support of small scale screening efforts and routine compound testing as well as mechanistic evaluation of inhibitors.
Daniel K. Treiber is a principal inventor and developer of KINOMEscan & BROMOscan technologies and has more than fifteen years of experience in the areas of biochemical and cellular assay development and small molecule kinase inhibitor drug discovery and pre-clinical development. Dr. Treiber came to DiscoveRx from Ambit Biosciences, where, in addition to his contributions to KINOMEscan, he held leadership positions on multiple oncology-focused drug discovery teams and contributed to the strategic design of quizartinib (AC220), a FLT3 inhibitor shown in phase II clinical trials to be a highly efficacious for the treatment of acute myelogenous leukemia (AML). While with Ambit, Dr. Treiber successfully applied KINOMEscan technology to several lead discovery and optimization programs. Dr. Treiber received his Ph.D. in toxicology from MIT and completed postdoctoral studies in the MIT chemistry department. Dr. Treiber received a B.A. in biology from Middlebury College.
*Separate registration is required